HRT Reports 'Remarkable Achievement' In OTC Naloxone Phase 1 Clinical Trial Results

 
• By Hannah Daniel

Harm Reduction Therapeutics CEO Michael Hufford says non-profit is “rapidly moving forward” with OTC naloxone NDA.

Source: Alamy (Alamy Stock Photo)

More from Rx-to-OTC Switch

More from Health